Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 12, 2012, Pages 4717-4723

  Ou, Horng Yih ^a   Yang, Yi Ching ^a   Wu, Hung Tsung ^b   Wu, Jin Shang ^a   Lu, Feng Hwa ^a   Chang, Chih Jen ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FETUIN A; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; FETUIN A BLOOD LEVEL; GLUCOSE TOLERANCE; HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; ALPHA-2-HS-GLYCOPROTEIN; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FASTING; FATTY LIVER; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; UP-REGULATION;

EID: 84870736698     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2414     Document Type: Article

References (33)

1. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J 2010 Prevalence of diabetes among men and women in China. N Engl J Med 362:1090-1101
2. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C 2000 Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132:112-117 (Pubitemid 30044177)
3. Tolman KG, Fonseca V, Dalpiaz A, Tan MH 2007 Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 30:734-743 (Pubitemid 46354365)
4. DeFronzo RA, Abdul-Ghani M 2011 Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 108:3B-24B
5. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK 2009 NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 104:861-867
6. Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh TCIN-JGHF, Pmid 2010 Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 25:352-356
7. Kantartzis K, Machann J, Schick F, Fritsche A, Häring HU, Stefan N 2010 The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia 53:882-889
8. Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS 2009 Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract 84:84-91
9. Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, Hardies J, Cusi K 2012 Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 35:873-878
10. Stefan N, Kantartzis K, Häring HU 2008 Causes and metabolic consequences of fatty liver. Endocr Rev 29:939-960
11. Tönjes A, Fasshauer M, Kratzsch J, Stumvoll M, Blüher M 2010 Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One 5:e13911
12. Denecke B, Gräber S, Schäfer C, Heiss A, Wöltje M, Jahnen-Dechent W 2003 Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J 376:135-145 (Pubitemid 37487209)
13. Srinivas PR, Wagner AS, Reddy LV, Deutsch DD, Leon MA, Goustin AS, Grunberger G 1993 Serum α2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 7:1445-1455
14. Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, Ray S, Majumdar SS, Bhattacharya S 2012 Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 10.1038/nm. 2851
15. Mathews ST, Singh GP, Ranalletta M, Cintron VJ, Qiang X, Goustin AS, Jen KL, Charron MJ, Jahnen-Dechent W, Grunberger G 2002 Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 51:2450-2458 (Pubitemid 34827393)
16. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Kröber SM, Machicao F, Fritsche A, Häring HU 2006 α2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29:853-857 (Pubitemid 44115306)
17. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA 2006 Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 113:1760-1767 (Pubitemid 43958469)
18. Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, Koyama H, Shoji T, Inaba M, Nishizawa Y 2006 Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care 29:468 (Pubitemid 44106548)
19. Ishibashi A, Ikeda Y, Ohguro T, Kumon Y, Yamanaka S, Takata H, Inoue M, Suehiro T, Terada Y 2010 Serum fetuin-A is an independent marker of insulin resistance in Japanese men. J Atheroscler Thromb 17:925-933
20. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, Häring HU, Boeing H, Fritsche A 2008 Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 118:2555-2562
21. Ou HY, Yang YC, Wu HT, Wu JS, Lu FH, Chang CJ 2011 Serum fetuin-A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes. Clin Endocrinol (Oxf) 75:450-455
22. Saverymuttu SH, Joseph AE, Maxwell JD 1986 Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 292:13-15 (Pubitemid 16175875)
23. Dasgupta S, Bhattacharya S, Biswas A, Majumdar SS, Mukhopadhyay S, Ray S, Bhattacharya S 2010 NF-κB mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance. Biochem J 429:451-462
24. Takata H, Ikeda Y, Suehiro T, Ishibashi A, Inoue M, Kumon Y, Terada Y 2009 High glucose induces transactivation of the α2-HS glycoprotein gene through the ERK1/2 signaling pathway. J Atheroscler Thromb 16:448-456
25. Ou HY, Wu HT, Hung HC, Yang YC, Wu JS, Chang CJ 2012 Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance. Endocrinology 153:2974-2984
26. Reinehr T, Roth CL 2008 Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab 93:4479-4485 (Pubitemid 352789550)
27. DECODE Study Group, the European Diabetes Epidemiology Group 2001 Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405
28. Qiao Q, Pyörälä K, Pyörälä M, Nissinen A, Lindström J, Tilvis R, Tuomilehto J 2002 Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 23:1267-1275 (Pubitemid 35238508)
29. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G 2005 Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54:3541-3546 (Pubitemid 43334347)
30. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, Diamant MCINJHA, Pmid 2007 Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191:391-396
31. Mori K, Emoto M, Araki T, Yokoyama H, Teramura M, Lee E, Motoyama K, Koyama H, Shoji T, Inaba M, Nishizawa Y 2007 Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf) 66:246-250 (Pubitemid 46096145)
32. Fabian E, Bogner M, Elmadfa I 2012 Age-related modification of antioxidant enzyme activities in relation to cardiovascular risk factors. Eur J Clin Invest 42:42-48
33. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F 2009 Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 51:433-445